Richard Karl Plemper

This paper develops a bireporter recombinant SARS-CoV-2 Omicron BA.5 strain for tracking viral infections and testing antivirals and neutralizing antibodies in vitro and in vivo.

This paper develops a recombinant SARS-CoV-2 virus expressing reporter genes to track viral infection in wild-type mice, showing it can be used for vaccine and antiviral research without needing transgenic models.

This study identifies and characterizes a SARS-CoV-2 Mpro G23 deletion mutant resistant to ensitrelvir but not to nirmatrelvir or remdesivir.

This paper develops a new antiviral compound, GHP-88310, showing high tolerability and oral efficacy against measles and respiratory paramyxoviruses in animal models.

This study identifies novel small-molecule inhibitors of Chikungunya virus replication through high-throughput screening and characterizes their mechanism of action and resistance profiles.

This study identifies mutations in VEEV nsP4 that reduce susceptibility to 4-FlU, shows these mutations do not fully prevent 4-FlU's therapeutic effect in mice, and highlights its potential as an antiviral for alphavirus encephalitis.

This study shows that aged Roborovski dwarf hamsters infected with SARS-CoV-2 develop severe lung inflammation, impaired respiratory function, and chronic pneumonia, which can be mitigated by antiviral treatment.

This paper develops an attenuated SARS-CoV-2 virus expressing nanoluciferase to identify and validate drug-resistant mutants to nirmatrelvir without using wild-type virus.

SFB colonization reprograms alveolar macrophages to resist depletion and enhance bacterial clearance post-influenza infection.

This paper develops tetracistronic minigenomes for henipaviruses to model their life cycle outside high biocontainment, revealing Cedar virus replicase promiscuity and functional GhV replicase with antiviral efficacy.

This study evaluates late-onset antiviral treatment in immunocompromised mice with persistent SARS-CoV-2 infection, finding that 4-FlU significantly reduces virus load, while paxlovid causes viral rebound.

This study identifies mutations conferring resistance to 4-fluorouridine in influenza viruses and shows that resistant variants are attenuated in vivo and can be overcome by higher drug doses.

The paper shows that segmented filamentous bacteria reprogram alveolar macrophages to enhance non-inflammatory defense against respiratory viruses.